Polymorphisms of the UDP-glucuronosyl transferase 1A Genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy

Tohoku Journal of Experimental Medicine

Volumn 229, Issue 2, 2013, Pages 107-114

  Inoue, Kazuyuki ^a   Sonobe, Momoyo ^a   Kawamura, Yukinori ^a   Etoh, Takashi ^b   Takagi, Masakazu ^b   Matsumura, Takashi ^b   Kikuyama, Masataka ^b   Kimura, Midori ^b   Minami, Sato ^b   Utsuki, Hiroaki ^b   Yamazaki, Tomoaki ^b   Suzuki, Takayo ^b   Tsuji, Daiki ^a   Hayashi, Hideki ^a   Itoh, Kunihiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

Author keywords

Adverse event; Genetic polymorphism; Irinotecan; SN 38; UGT1A

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CATALYSIS; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; MALE; NEUTROPENIA; STOMACH CANCER; URIDINE DIPHOSPHATE GLUCURONOSYL TRANSFERASE 1A1 GENE; URIDINE DIPHOSPHATE GLUCURONOSYL TRANSFERASE 1A7 GENE; URIDINE DIPHOSPHATE GLUCURONOSYL TRANSFERASE 1A9 GENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLONIC NEOPLASMS; DIARRHEA; DRUG TOXICITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PHARMACOGENETICS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 84876327926     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.229.107     Document Type: Article

References (30)

1. Ando, M. Ando, Y. Sekido, Y. Ando, M. Shimokata, K. & Hasegawa, Y.(2002) Genetic polymorphisms of the UDPglucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn. J. Cancer Res. 93, 591-597.
2. Ando, Y. Saka, H. Ando, M. Sawa, T. Muro, K. Ueoka, H. Yokoyama, A. Saitoh, S. Shimokata, K. & Hasegawa, Y.(2000) Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926.
3. Aono, S. Yamada, Y. Keino, H. Hanada, N. Nakagawa, T. Sasaoka, Y. Yazawa, T. Sato, H. & Koiwai, O.(1993) Identification of defect in the genes for bilirubin UDP-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type II. Biochem. Biophys. Res. Commun. 197, 1239-1244.
4. Araki, K. Fujita, K. Ando, Y. Nagashima, F. Yamamoto, W. Endo, H. Miya, T. Kodama, K. Narabayashi, M. & Sasaki, Y.(2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 97, 1255-1259.
5. Boku, N. Ohtsu, A. Shimada, Y. Shirao, K. Seki, S. Saito, H. Sakata, Y. & Hyodo, I.(1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 17, 319-323.
6. Bosma, P.J. Chowdhury, J.R. Bakker, C. Gantla, S. de Boer, A. Oostra, B.A. Lindhout, D. Tytgat, G.N. Jansen, P.L. Oude, Elferink, R.P. & Chowdhury, N.R.(1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175.
7. Carlini, L.E. Meropol, N.J. Bever, J. Andria, M.L. Hill, T. Gold, P. Rogatko, A. Wang, H. & Blanchard, R.L.(2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11, 1226-1236.
8. Cersosimo, R.J.(1998) Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann. Pharmacother. 32, 1324-1333.
9. Dodds, H.M. Haaz, M.C. Riou, J.F. Robert, J. & Rivory, L.P.(1998) Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther. 286, 578-583.
10. Douillard, J.Y. Cunningham, D. Roth, A.D. Navarro, M. James, R.D. Karasek, P. Jandik, P. Iveson, T. Carmichael, J. Alakl, M. Gruia, G. Awad, L. & Rougier, P.(2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041-1047.
11. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.(2009) Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11, 15-20.
12. Fuchs, C.S. Marshall, J. Mitchell, E. Wierzbicki, R. Ganju, V. Jeffery, M. Schulz, J. Richards, D. Soufi-Mahjoubi, R. Wang, B. & Barrueco, J.(2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol. 25, 4779-4786.
13. Fukuoka, M. Niitani, H. Suzuki, A. Motomiya, M. Hasegawa, K. Nishiwaki, Y. Kuriyama, T. Ariyoshi, Y. Negoro, S. & Masuda, N.(1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10, 16-20.
14. Gagné, J.F. Montminylg, V. Belanger, P. Journault, K. Gaucher, G. & Guillemette,C.(2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62, 608-617.
15. Gupta, E. Lestingi, T.M. Mick, R. Ramirez, J. Vokes, E.E. & Ratain, M.J.(1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54, 3723-3725.
16. Han, J.Y. Lim, H.S. Shin, E.S. Yoo, Y.K. Park, Y.H. Lee, J.E. Jang, I.J. Lee, D.H. & Lee, J.S.(2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244.
17. Han, J.Y. Lim, H.S. Park, Y.H. Lee, S.Y. & Lee, J.S.(2009) Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer, 63, 115-120.
18. Innocenti, F. Undevia, S.D. Iyer, L. Chen, P.X. Das, S. Kocherginsky, M. Karrison, T. Janisch, L. Ramírez, J. Rudin, C.M. Vokes, E.E. & Ratain, M.J.(2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388.
19. Kaniwa, N. Kurose, K. Jinno, H. Tanaka-Kagawa, T. Saito, Y. Saeki, M. Sawada, J. Tohkin, M. & Hasegawa, R.(2005) Racial variability in haplotype frequencies of UGT1A1 andglucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab. Dispos. 33, 458-465.
20. Kawato, Y. Aonuma, M. Hirota, Y. Kuga, H. & Sato, K.(1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187-4191.
21. Lampe, J.W. Bigler, J. Horner, N.K. & Potter, J.D.(1999) UDPglucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics, 9, 341-349.
22. Minami, H. Sai, K. Saeki, M. Saito, Y. Ozawa, S. Suzuki, K. Kaniwa, N. Sawada, J. Hamaguchi, T. Yamamoto, N. Shirao, K. Yamada, Y. Ohmatsu, H. Kubota, K. Yoshida, T. Ohtsu, A. & Saijo, N.(2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics, 17, 497-504.
23. Negoro, S. Masuda, N. Takada, Y. Sugiura, T. Kudoh, S. Katakami, N. Ariyoshi, Y. Ohashi, Y. Niitani, H.& Fukuoka, M.; CPT-11 Lung Cancer Study Group West.(2003) Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer, 88, 335-341.
24. Sai, K. Saeki, M. Saito, Y. Ozawa, S. Katori, N. Jinno, H. Hasegawa, R. Kaniwa, N. Sawada, J. Komamura, K. Ueno, K. Kamakura, S. Kitakaze, M. Kitamura, Y. Kamatani, N. Minami, H. Ohtsu, A. Shirao, K. Yoshida, T. & Saijo, N.(2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecanadministered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515.
25. Shimada, Y. Yoshino, M. Wakui, A. Nakao, I. Futatsuki, K. Sakata, Y. Kambe, M. Taguchi, T. & Ogawa, N.(1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. 11, 909-913.
26. Sugatani, J. Yamakawa, K. Yoshinari, K. Machida, T. Takagi, H. Mori, M. Kakizaki, S. Sueyoshi, T. Negishi, M. & Miwa, M.(2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 292, 492-497.
27. Toffoli, G. Cecchin, E. Corona, G. & Boiocchi, M.(2003) Pharmacogenetics of irinotecan. Curr. Med. Chem. Anticancer Agents, 3, 225-237.
28. van der Logt, E.M. Bergevoet, S.M. Roelofs, H.M. van Hooijdonk, Z. te Morsche, R.H. Wobbes, T., de Kok, J.B. Nagengast, F.M. & Peters, W.H.(2004) Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis, 25, 2407-2415.
29. Villeneuve, L. Girard, H. Fortier, L.C., Gagné, J.F. & Guillemette, C,(2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther. 307, 117-128.
30. Yamanaka, H. Nakajima, M. Katoh, M. Hara, Y. Tachibana, O. Yamashita, J. McLeod, H.L. & Yokoi, T.(2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics, 14, 329-332.